Eli Lilly has taken another step in transforming itself from a fully integrated big pharma to a partnership arrangement, which it now calls a Fully Integrated Pharmaceutical Network (FIPNet). The goal is to foster open collaboration between Lilly and global laboratory researchers. Lilly calls its new program the Phenotypic Drug Discovery Initiative, or PD2 (pronounced PD-squared). Lilly is offering a free-of-charge use to outside researchers of its disease-state assays, complete with a secure web portal, which will evaluate the therapeutic potential of externally-developed synthesized compounds. More details...

Stock Symbol: (NYSE: LLY)